All In Biotech

Drugs by condition

Drugs approved for head and neck cancer

Brand-name prescription drugs and biologics whose FDA label lists head and neck cancer as an approved use. Matched on the label phrases: "head and neck".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

24

Still marketed, NDA or BLA

Drug classes

9

Novel drugs

11

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for head and neck cancer.

  • Ambelvist (Gadoquatrane) · Bayer Healthcare NovelOrphanJun 12, 2026
  • Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj) · Janssen Biotech Priority reviewDec 17, 2025
  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
  • Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024
  • Beizray (Docetaxel) · Zhuhai Oct 23, 2024

All approved drugs for head and neck cancer, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 64 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Endoglycosidase (3)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
  • Rybrevant Faspro Amivantamab and Hyaluronidase-Lpuj · Janssen Biotech · 2025
  • Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024

Microtubule Inhibitor (3)

Programmed Death Receptor-1 Blocking Antibody (2)

  • Opdivo Nivolumab · Bristol Myers Squibb · 2014
  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014

Paramagnetic Contrast Agent (2)

Epidermal Growth Factor Receptor Antagonist (1)

  • Erbitux Cetuximab · Imclone · 2004

Antimetabolite (1)

  • Droxia Hydroxyurea · Waylis Therap · 1967

Nonsteroidal Anti-inflammatory Drug (1)

  • Zynrelef Kit Bupivacaine, Meloxicam · Heron Theraps INC · 2021

Thiazide Diuretic (1)

  • Vaseretic Enalapril Maleate, Hydrochlorothiazide · Bausch · 1986

Class not listed in FDA's data (10)

Drugs in development for head and neck cancer

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • DomvanalimabAB154, GS-0154Phase 310 trials

    Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer

  • SI-B001Phase 39 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck

  • LBL-007AlcestobartPhase 38 trials

    BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer

  • JMT101Phase 37 trials

    Shanghai JMT-Bio Inc. · Local Advanced or Metastatic NSCLC, Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy

  • PucotenlimabHX008Phase 36 trials

    Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • PetosemtamabMCLA-158, GEN1158Phase 35 trials

    Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors

  • SYS6002Phase 35 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors

  • MonalizumabIPH2201Phase 34 trials

    AstraZeneca · Non-small Cell Lung Cancer, Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck

  • MRG003Phase 34 trials

    Lepu Biopharma Co., Ltd. · Recurrent or Metastatic Nasopharyngeal Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Advanced Solid Tumors

  • APG-157Phase 33 trials

    Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx

1 discontinued brand-name drugs whose label still names it

More on head and neck cancer: recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.